3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
8
Head and Neck Neoplasms
3
Carcinoma, Squamous Cell
3
Thyroid Neoplasms
1
Smoking
1
Ovarian Neoplasms
1
Nasopharyngeal Carcinoma
1
Laryngeal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Iodine-131
21
lenvatinib
17
Magnetic Resonance Spectroscopy
17
trametinib
13
Sorafenib
13
Thyrotropin Alfa
12
pembrolizumab
11
dabrafenib
11
Thyroidectomy
10
Surgical Procedures, Operative
10
Thyroxine
9
Paclitaxel
9
vandetanib
8
selpercatinib
8
Sunitinib
7
Nivolumab
7
Fluorodeoxyglucose F18
7
cabozantinib
6
anlotinib
6
Everolimus
6
Biopsy
6
pazopanib
5
Vemurafenib
5
Triiodothyronine
5
Specimen Handling
5
Saline Solution
5
Radiotherapy
5
Radiofrequency Ablation
5
Iodine-124
5
Cyclophosphamide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
olaparib
×
Head & Neck
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled